60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals Concludes Babesiosis Trial Enrollment, Plans January 2027 Data Readout

60 Degrees Pharmaceuticals announced its decision to conclude enrollment in its randomized clinical study of tafenoquine for severe babesiosis at 30 subjects, rather than the initially planned 33. The company plans to unblind the study and report primary and secondary endpoint results in January 2027. Concurrently, 60 Degrees will request a pre-sNDA meeting with the U.S. FDA in January 2027 to discuss data requirements and a potential regulatory pathway, including an accelerated approval based on expanded access data and NAT-based molecular clearance as a surrogate endpoint. An interim analysis by the DSMB recommended completing the study with 33 patients, but the company opted to conclude early due to limited incremental statistical power and the seasonal nature of babesiosis, with no safety signals identified.

• 60 Degrees Pharmaceuticals has decided to conclude enrollment for its randomized clinical study of tafenoquine in hospitalized severe babesiosis patients at 30 subjects. The company anticipates unblinding the study and reporting both primary and secondary endpoint results in January 2027, marking a critical milestone for the potential treatment.
• An interim analysis by the Data Safety Monitoring Board (DSMB) recommended completing the study with the originally planned 33 patients. However, 60 Degrees Pharmaceuticals chose to conclude enrollment at 30 subjects, citing the limited incremental statistical power from three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027. No safety signals were identified during the DSMB review.
• The company plans to request a pre-sNDA meeting with the FDA in January 2027 to discuss the regulatory pathway for tafenoquine in babesiosis, particularly for severe and/or treatment-refractory disease. This strategy includes exploring an accelerated approval pathway, potentially leveraging published case reports and expanded access study data, and proposing NAT-based molecular clearance as a surrogate endpoint.
• Babesiosis currently lacks an FDA-approved treatment or vaccine, representing a significant unmet medical need, especially for immunocompromised patients with relapsing or treatment-refractory disease. While tafenoquine is approved for malaria prevention, 60 Degrees Pharmaceuticals is investigating its potential for babesiosis, supported by existing case reports and preliminary molecular cure data from its expanded access study (NCT06478641).

Tafenoquine's Severe Babesiosis Trial: Design and Upcoming Results

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

Addressing Critical Gaps in Severe and Refractory Babesiosis Treatment

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

Charting a Regulatory Path for Tafenoquine in Babesiosis with FDA

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

Tafenoquine's Accelerated Path: A Strategic Bet in Babesiosis

The landscape of rare infectious diseases often presents unique challenges for drug development, and 60 Degrees Pharmaceuticals' latest move with tafenoquine for severe babesiosis exemplifies a strategic approach to navigate these complexities. Babesiosis, particularly its severe form, represents a significant unmet medical need, with current treatment options sometimes limited or associated with considerable morbidity. The company's decision to conclude its randomized clinical study at 30 subjects, slightly below the initial target and a DSMB recommendation, is a calculated maneuver. This choice, driven by considerations of incremental statistical power and the seasonal nature of the disease, coupled with a clean safety profile to date, suggests a pragmatic focus on efficiency and speed.

This efficiency is further underscored by the ambitious regulatory pathway being pursued: accelerated approval. This strategy hinges on two critical components: leveraging existing expanded access data and proposing NAT-based molecular clearance as a surrogate endpoint. If the FDA accepts this surrogate, it could dramatically shorten the time to market, offering a novel therapy to patients much sooner than a traditional approval pathway. Such a precedent would not only benefit tafenoquine but could also pave the way for future drug development in babesiosis by validating a key biomarker.

However, this accelerated path is not without its inherent risks. The primary challenge lies in securing FDA agreement on NAT-based molecular clearance as a valid and sufficient surrogate endpoint for accelerated approval. Regulatory bodies often require robust evidence linking surrogate endpoints to meaningful clinical outcomes, and any skepticism could necessitate further, potentially time-consuming, clinical trials. Furthermore, while expanded access data can provide valuable real-world insights, its retrospective nature and potential for heterogeneity might not always satisfy the stringent data quality requirements for regulatory submission. Finally, the slightly reduced patient cohort, despite the company's rationale, introduces a subtle risk regarding the statistical robustness of the efficacy signal, which could be scrutinized during regulatory review. The coming months, leading up to the unblinding of results and the pre-sNDA meeting, will be pivotal in determining whether this strategic bet pays off, potentially reshaping the treatment paradigm for severe babesiosis.